Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comment on "treat-to-target in spondyloarthritis: implications for clinical trial designs".

Literature DB >> 25223824

Comment on "treat-to-target in spondyloarthritis: implications for clinical trial designs".

Daniel Wendling¹, Clément Prati.

Abstract

Entities: Disease

Mesh：

Year: 2014 PMID： 25223824 DOI： 10.1007/s40265-014-0288-3

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

× No keyword cloud information.

16 in total

1. Overdiagnosing early spondyloarthritis: what are the risks?

Authors: Jean-Marie Berthelot; Benoît Le Goff; Yves Maugars
Journal: Joint Bone Spine Date: 2013-05-31 Impact factor: 4.929

2. Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?

Authors: Uta Kiltz; Xenofon Baraliakos; Jürgen Braun; Désiréé van der Heijde
Journal: Clin Exp Rheumatol Date: 2013-10-04 Impact factor: 4.473

3. Unanswered questions in the management of axial spondyloarthritis: an opinion piece.

Authors: Xenofon Baraliakos; Atul Deodhar
Journal: Clin Rheumatol Date: 2014 Impact factor: 2.980

4. Remission thresholds in spondyloarthritis: a prospective study in current practice.

Authors: Marie Godfrin-Valnet; Marc Puyraveau; Daniel Wendling
Journal: J Rheumatol Date: 2014-03 Impact factor: 4.666

5. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis.

Authors: Daniel Wendling; Cédric Lukas; Julien Paccou; Pascal Claudepierre; Laurence Carton; Bernard Combe; Philippe Goupille; Francis Guillemin; Christophe Hudry; Corinne Miceli-Richard; Maxime Dougados
Journal: Joint Bone Spine Date: 2014-01-10 Impact factor: 4.929

1. Author's reply to Wendling and Prati: "treat-to-target in spondyloarthritis: implications for clinical trial designs".

Authors: James Cheng-Chung Wei
Journal: Drugs Date: 2014-09 Impact factor: 9.546

1 in total

Comment on "treat-to-target in spondyloarthritis: implications for clinical trial designs".

1. Overdiagnosing early spondyloarthritis: what are the risks?

2. Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?

3. Unanswered questions in the management of axial spondyloarthritis: an opinion piece.

4. Remission thresholds in spondyloarthritis: a prospective study in current practice.

5. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis.

6. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.

7. Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what's in a name?

Review 8. Treat-to-target in spondyloarthritis: implications for clinical trial designs.

9. Spondyloarthritis. Treat-to-target in spondyloarthritis--do we have a plan?

Review 10. Early diagnosis and management are crucial in spondyloarthritis.

1. Author's reply to Wendling and Prati: "treat-to-target in spondyloarthritis: implications for clinical trial designs".